176 related articles for article (PubMed ID: 10589007)
1. Reduced in vivo allergenicity of Bet v 1d isoform, a natural component of birch pollen.
Arquint O; Helbling A; Crameri R; Ferreira F; Breitenbach M; Pichler WJ
J Allergy Clin Immunol; 1999 Dec; 104(6):1239-43. PubMed ID: 10589007
[TBL] [Abstract][Full Text] [Related]
2. Skin test evaluation of genetically engineered hypoallergenic derivatives of the major birch pollen allergen, Bet v 1: results obtained with a mix of two recombinant Bet v 1 fragments and recombinant Bet v 1 trimer in a Swedish population before the birch pollen season.
van Hage-Hamsten M; Kronqvist M; Zetterström O; Johansson E; Niederberger V; Vrtala S; Grönlund H; Grönneberg R; Valenta R
J Allergy Clin Immunol; 1999 Nov; 104(5):969-77. PubMed ID: 10550741
[TBL] [Abstract][Full Text] [Related]
3. Comparison of genetically engineered hypoallergenic rBet v 1 derivatives with rBet v 1 wild-type by skin prick and intradermal testing: results obtained in a French population.
Pauli G; Purohit A; Oster JP; De Blay F; Vrtala S; Niederberger V; Kraft D; Valenta R
Clin Exp Allergy; 2000 Aug; 30(8):1076-84. PubMed ID: 10931114
[TBL] [Abstract][Full Text] [Related]
4. Recombinant birch pollen allergens (rBet v 1 and rBet v 2) contain most of the IgE epitopes present in birch, alder, hornbeam, hazel, and oak pollen: a quantitative IgE inhibition study with sera from different populations.
Niederberger V; Pauli G; Grönlund H; Fröschl R; Rumpold H; Kraft D; Valenta R; Spitzauer S
J Allergy Clin Immunol; 1998 Oct; 102(4 Pt 1):579-91. PubMed ID: 9802365
[TBL] [Abstract][Full Text] [Related]
5. Dissection of immunoglobulin E and T lymphocyte reactivity of isoforms of the major birch pollen allergen Bet v 1: potential use of hypoallergenic isoforms for immunotherapy.
Ferreira F; Hirtenlehner K; Jilek A; Godnik-Cvar J; Breiteneder H; Grimm R; Hoffmann-Sommergruber K; Scheiner O; Kraft D; Breitenbach M; Rheinberger HJ; Ebner C
J Exp Med; 1996 Feb; 183(2):599-609. PubMed ID: 8627171
[TBL] [Abstract][Full Text] [Related]
6. Induction of IgE antibodies in mice and rhesus monkeys with recombinant birch pollen allergens: different allergenicity of Bet v 1 and Bet v 2.
Vrtala S; Mayer P; Ferreira F; Susani M; Sehon AH; Kraft D; Valenta R
J Allergy Clin Immunol; 1996 Nov; 98(5 Pt 1):913-21. PubMed ID: 8939154
[TBL] [Abstract][Full Text] [Related]
7. Heterogeneity in the polyclonal T cell response to birch pollen allergens.
Dormann D; Montermann E; Klimek L; Weber B; Ebner C; Valenta R; Kraft D; Reske-Kunz AB
Int Arch Allergy Immunol; 1997 Nov; 114(3):272-7. PubMed ID: 9363909
[TBL] [Abstract][Full Text] [Related]
8. Characterization of wild-type recombinant Bet v 1a as a candidate vaccine against birch pollen allergy.
Batard T; Didierlaurent A; Chabre H; Mothes N; Bussières L; Bohle B; Couret MN; Ball T; Lemoine P; Focks Tejkl M; Chenal A; Clément G; Dupont F; Valent P; Krauth MT; André C; Valenta R; Moingeon P
Int Arch Allergy Immunol; 2005 Mar; 136(3):239-49. PubMed ID: 15722633
[TBL] [Abstract][Full Text] [Related]
9. Skin testing with recombinant allergens rBet v 1 and birch profilin, rBet v 2: diagnostic value for birch pollen and associated allergies.
Pauli G; Oster JP; Deviller P; Heiss S; Bessot JC; Susani M; Ferreira F; Kraft D; Valenta R
J Allergy Clin Immunol; 1996 May; 97(5):1100-9. PubMed ID: 8626988
[TBL] [Abstract][Full Text] [Related]
10. Fagales pollen sensitization in a birch-free area: a respiratory cohort survey using Fagales pollen extracts and birch recombinant allergens (rBet v 1, rBet v 2, rBet v 4).
Mari A; Wallner M; Ferreira F
Clin Exp Allergy; 2003 Oct; 33(10):1419-28. PubMed ID: 14519150
[TBL] [Abstract][Full Text] [Related]
11. Frequent occurrence of T cell-mediated late reactions revealed by atopy patch testing with hypoallergenic rBet v 1 fragments.
Campana R; Moritz K; Marth K; Neubauer A; Huber H; Henning R; Blatt K; Hoermann G; Brodie TM; Kaider A; Valent P; Sallusto F; Wöhrl S; Valenta R
J Allergy Clin Immunol; 2016 Feb; 137(2):601-609.e8. PubMed ID: 26518092
[TBL] [Abstract][Full Text] [Related]
12. Recombinant Bet v 1, the major birch pollen allergen, induces hypersensitivity reactions equal to those induced by natural Bet v 1 in the airways of patients allergic to tree pollen.
Godnic-Cvar J; Susani M; Breiteneder H; Berger A; Havelec L; Waldhör T; Hirschwehr R; Valenta R; Scheiner O; Rüdiger H; Kraft D; Ebner C
J Allergy Clin Immunol; 1997 Mar; 99(3):354-9. PubMed ID: 9058691
[TBL] [Abstract][Full Text] [Related]
13. In vitro and in vivo allergenicity of recombinant Bet v 1 compared to the reactivity of natural birch pollen extract.
Tresch S; Holzmann D; Baumann S; Blaser K; Wüthrich B; Crameri R; Schmid-Grendelmeier P
Clin Exp Allergy; 2003 Aug; 33(8):1153-8. PubMed ID: 12911792
[TBL] [Abstract][Full Text] [Related]
14. Serological and skin-test diagnosis of birch pollen allergy with recombinant Bet v I, the major birch pollen allergen.
Menz G; Dolecek C; Schönheit-Kenn U; Ferreira F; Moser M; Schneider T; Suter M; Boltz-Nitulescu G; Ebner C; Kraft D; Valenta R
Clin Exp Allergy; 1996 Jan; 26(1):50-60. PubMed ID: 8789543
[TBL] [Abstract][Full Text] [Related]
15. Vaccines for birch pollen allergy based on genetically engineered hypoallergenic derivatives of the major birch pollen allergen, Bet v 1.
Mahler V; Vrtala S; Kuss O; Diepgen TL; Suck R; Cromwell O; Fiebig H; Hartl A; Thalhamer J; Schuler G; Kraft D; Valenta R
Clin Exp Allergy; 2004 Jan; 34(1):115-22. PubMed ID: 14720271
[TBL] [Abstract][Full Text] [Related]
16. Cytokine and antibody responses in birch-pollen-allergic patients treated with genetically modified derivatives of the major birch pollen allergen Bet v 1.
Gafvelin G; Thunberg S; Kronqvist M; Grönlund H; Grönneberg R; Troye-Blomberg M; Akdis M; Fiebig H; Purohit A; Horak F; Reisinger J; Niederberger V; Akdis CA; Cromwell O; Pauli G; Valenta R; van Hage M
Int Arch Allergy Immunol; 2005 Sep; 138(1):59-66. PubMed ID: 16103688
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of recombinant birch pollen vaccine for the treatment of birch-allergic rhinoconjunctivitis.
Pauli G; Larsen TH; Rak S; Horak F; Pastorello E; Valenta R; Purohit A; Arvidsson M; Kavina A; Schroeder JW; Mothes N; Spitzauer S; Montagut A; Galvain S; Melac M; André C; Poulsen LK; Malling HJ
J Allergy Clin Immunol; 2008 Nov; 122(5):951-60. PubMed ID: 19000581
[TBL] [Abstract][Full Text] [Related]
18. Quality and potency profile of eight recombinant isoallergens, largely mimicking total Bet v 1-specific IgE binding of birch pollen.
Seutter von Loetzen C; Reuter A; Spiric J; Schulenborg T; Bellinghausen I; Völker E; Vogel L; Rösch P; Schiller D
Clin Exp Allergy; 2019 May; 49(5):712-723. PubMed ID: 30706562
[TBL] [Abstract][Full Text] [Related]
19. Bet v 1, the major birch pollen allergen, conjugated to crystalline bacterial cell surface proteins, expands allergen-specific T cells of the Th1/Th0 phenotype in vitro by induction of IL-12.
Jahn-Schmid B; Siemann U; Zenker A; Bohle B; Messner P; Unger FM; Sleytr UB; Scheiner O; Kraft D; Ebner C
Int Immunol; 1997 Dec; 9(12):1867-74. PubMed ID: 9466314
[TBL] [Abstract][Full Text] [Related]
20. Molecular cloning and characterization of a birch pollen minor allergen, Bet v 5, belonging to a family of isoflavone reductase-related proteins.
Karamloo F; Schmitz N; Scheurer S; Foetisch K; Hoffmann A; Haustein D; Vieths S
J Allergy Clin Immunol; 1999 Nov; 104(5):991-9. PubMed ID: 10550744
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
